Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways - Gilde Healthcare

Digital Noema Telehealth and Lumeon Partner to Optimize Telemedicine Pathways

February 20, 2017

LONDON AND NEW YORK – Today at HIMSS, Lumeon, a leading digital health company, and Digital Noema Telehealth (DN Telehealth), a provider of telemedicine and remote patient monitoring, announce they are partnering to optimize care pathways for telemedicine reimbursements.

DN Telehealth maximizes collaboration compatibility for its clients and their patients, in real-time, extending consultations beyond a physical clinical setting to include fully secure, web browser-based conferencing sessions.  The solution allows clinicians, caregivers and patients to extend care coordination to go beyond traditional care models, to optimize care and promote patient engagement of any “at risk” patient population, in a fully HIPAA-compliant environment.

Lumeon’s Care Pathway Manager seamlessly integrates clinical and administrative systems, and gives providers the ability to design and automate their own pathway rules, so that each patient is automatically progressed through their personal care journey based on their individual data.

“We’ve been looking for a care pathway automation partner for quite some time,” said Roque Espinal-Valdez, founder, and CEO of DN Telehealth. “With Lumeon’s functionality to automate and orchestrate the care pathway, previously manual tasks are eliminated and we can ensure that reimbursable elements are consistently used to deliver predictable outcomes for our customers in the managed care market.”

“Working with DN Telehealth provides us with the opportunity to address one of the fastest growing sectors within healthcare,” said Robbie Hughes, Lumeon CEO. “At the same time, our platform will enable customers of DN Telehealth to automate and orchestrate their care pathways to maximize reimbursement and improve efficiency of care delivery.”

The solution is available in North American and European markets from March 2017.

More news

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
October 14, 2025

Gilde Healthcare company CatalYm announces first patient dosed in Phase 2b trial evaluating Visugromab in combination with chemoimmunotherapy as frst-line treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company’s anti-GDF-15 antibody visugromab, in combination with standard-of-care...
September 30, 2025